« Back
Home /
Recombinant Monkeypox Virus IFN-alpha/beta-receptor-like Secreted Glycoprotein B16R

Recombinant Monkeypox Virus IFN-alpha/beta-receptor-like Secreted Glycoprotein B16R

Item no.	230-30236-100
Manufacturer	Raybiotech
Amount	100 ug
Category	Peptides & Proteins Recombinant Proteins Immunoprecipitation Western Blot ELISA Immunostaining Dot Blot
Type	Proteins Recombinant
Format	Liquid
Applications	WB, IP, ELISA, Dot
Specific against	Virus, Monkeypox
Host	HEK293 cells
Conjugate/Tag	HIS
Purity	>90%
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Shipping Condition	Cool pack
Available
Manufacturer - Applications	Functional Assay, Protein-protein Interaction, Post-translational Modifications, ELISA, EIA, Western Blotting, Dot Blotting, Immunoprecipitation, Protein Array, etc.
Manufacturer - Category	Proteins\|Recombinant Proteins\|Viral Proteins
Manufacturer - Conjugate / Tag	C-terminal His-tag
Shipping Temperature	Blue ice
Storage Conditions	-20°C
Molecular Weight	Recombinant protein product has a calculated molecular mass of ∼38 kDa. Due to the abundant glycosylation, it migrates as approximately ∼50 Da protein bands in SDS-PAGE under DTT, beta-mercaptoethanol reducing conditions.
Description	Recombinant Monkeypox virus IFN-alpha/beta-receptor-like secreted glycoprotein (B16R) with a C-terminal His-tag, derived from the transfected HEK293 cells.
Purity determined by	SDS-PAGE under reducing conditions and visualized by Coomassie blue staining
Gene Symbols	B16R
UNSPSC Code	12352202
Formulation	Filtered solution in PBS with 1% mannitol and 5% trehalose
Expressed Region	His21-Glu352
Purification	His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC)
Concentration	Determined by BCA protein assay
Endotoxin Level	<0.5 EU per µg of the protein as determined by the LAL method
SDS-PAGE Image	Figure 1. Deglycosylation analysis of purified recombinant proteins. The same amount of purified proteins were untreated (Lane 2) or treated with protein deglycosylation enzymes under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one reduced band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated.Lane 1: protein standard ladder (kDa).Lane 2: untreated protein.Lane 3: treated protein with deglycosylation enzymes under native conditions.Lane 4: treated protein with deglycosylation enzymes under denature conditions.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.